Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

Table 1 Current clinical presentation and management of Hodgkin lymphoma

Histology	Incidence (%)	Age at diagnosis	Clinical characteristics	Treatment	Outcome, PFS (%)
cHL	95	Bimodal
NSCHL	70	Young adults (10 to 30 years)	Frequent mediastinal involvement	ABVD±RT	80
MCCHL	10 to 25	Bimodal distribution, 3rd to 7th decade	Infrequent mediastinal involvement	ABVD±RT	<80
LDCHL	1	Bimodal distribution, 3rd to 7th decade	Infrequent mediastinal involvement	ABVD±RT	<80
LRCHL	1	Bimodal distribution, 3rd to 7th decade	Infrequent mediastinal involvement	ABVD±RT	>90
NLPHL	5	4th decade	Infrequent mediastinal involvement	ABVD±RT, rituximab	Good prognosis, multiple relapses

ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; cHL, classical Hodgkin lymphoma; LDCHL, lymphocyte-depletion classical Hodgkin lymphoma; LRCHL, lymphocyte-rich classical Hodgkin lymphoma; MCCHL, mixed-cellularity classical Hodgkin lymphoma; NLPHL, nodular lymphocyte-predominant Hodgkin lymphoma; NSCHL, nodular-sclerosis classical Hodgkin lymphoma; PFS, progression-free survival; RT, radiotherapy.

ISSN: 1756-994X